Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study by Wilkinson, Nina et al.
See related commentary on pg 19 ORIGINAL ARTICLEDefining the Therapeutic Range for
Adalimumab and Predicting Response in
Psoriasis: A Multicenter Prospective
Observational Cohort Study
Nina Wilkinson1,9, Teresa Tsakok2,3,9, Nick Dand2, Karien Bloem4, Michael Duckworth2,
David Baudry2, Angela Pushpa-Rajah2, Christopher E.M. Griffiths5, Nick J. Reynolds6,
Jonathan Barker2,3, Richard B. Warren5, A. David Burden7, Theo Rispens4, Deborah Stocken8,10 and
Catherine Smith2,3,10, on behalf of the BSTOP study group and the PSORT consortiumBiologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs,
dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world
clinical utility of therapeutic drug monitoring in psoriasis. Within a multicenter (n ¼ 60) prospective observa-
tional cohort, 544 psoriasis patients were included who were receiving adalimumab monotherapy and had at
least one serum sample and Psoriasis Area and Severity Index (PASI) score available within the first year. We
present models giving individualized probabilities of response for any given drug level: a minimally effective
drug level of 3.2 mg/ml discriminates responders (PASI75 indicates 75% improvement in baseline PASI) from
nonresponders, and gives an estimated PASI75 probability of 65% (95% confidence interval ¼ 60e71). At 7 mg/ml,
PASI75 probability is 81% (95% CI ¼ 76e86); beyond 7 mg/ml, the drug level/response curve plateaus. Crucially,
drug levels are predictive of response 6 months later, whether sampled early or at steady state. We confirm
serum drug level to be the most important factor determining treatment response, highlighting the need to
take drug levels into account when searching for biomarkers of response. This real-world study with pragmatic
drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis
to direct treatment strategy, and is relevant to other inflammatory diseases.
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Biologic therapies have transformed the treatment paradigm
in immune-mediated inflammatory diseases (IMIDs). Com-
plete disease remission is now achievable in people with
psoriasis, rheumatoid arthritis (RA), and inflammatory bowel
disease (IBD), where inhibition of the inflammatory cytokine
tumor necrosis factor-a (TNF- a) remains the first-line bio-
logic strategy. However, there are wide variations in
response, with a significant number of patients not respond-
ing (primary treatment failure) or losing response over time
(secondary treatment failure) (Garces et al., 2013; Yanai and
Hanauer, 2011). Some of this heterogeneity may be
explained by differences in the amount of drug available at
the target tissue, which in turn is influenced by adherence
and pharmacokinetic covariates such as weight and drug
immunogenicity (formation of antidrug antibodies [ADAs]).
Therapeutic drug monitoring using measurement of serum
drug levels (a proxy for tissue levels) and/or ADAs thus holds
potential to optimize management, and a strong correlation
between TNF inhibitor serum trough levels, ADAs, and
treatment response has been described in IBD, RA, and
psoriasis (Baert et al., 2003; Chen et al., 2015; Lecluse et al.,
2010). Indeed, a recent study using adalimumab clinical trial
data in 1,212 psoriasis patients reported that responders at 16
weeks had higher adalimumab concentrations than non-
responders (6.3 vs. 2.2 mg/ml). Bodyweight was a significantestigative Dermatology. This is an open access
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116covariate in the pharmacokinetic model, and the presence of
ADAs resulted in lower adalimumab exposure and efficacy
(Mostafa et al., 2017).
Effective therapeutic drug monitoring requires the defini-
tion of a therapeutic range, and although parameters for
serum adalimumab levels have been proposed in the context
of several IMIDs (Menting et al., 2015; Pouw et al., 2015;
Roblin et al., 2014; Yarur et al., 2016), these have not yet
been validated in psoriasis patients. Furthermore, the utility
of drug level as a predictor of subsequent response has not
been investigated in psoriasis other than in a previous
preliminary study by our group (Mahil et al., 2013). Defining
clinical outcomes in IBD and RA is inherently challenging—
often relying on composite indices comprising patient-
reported criteria and nonspecific biochemical markers.
Psoriasis provides a disease model less encumbered by such
issues, because treatment response can be visually observed
and easily quantified. Furthermore, biologics are generally
used as monotherapy (whereas patients with IBD and RA are
often co-prescribed immunosuppressants such as metho-
trexate, known to reduce the formation of ADAs). Here, we
capitalize on a real-world bioresource from a large multi-
center cohort study, Biomarkers of Systemic Treatment
Outcomes in Psoriasis (BSTOP), within the UK pharmacovi-
gilance registry British Association of Dermatologists Bio-
logic Interventions Registry (BADBIR), to investigate the
clinical utility of therapeutic drug monitoring as applied to
the exemplar TNF inhibitor adalimumab. This work is
particularly timely with the imminent release of adalimumab
biosimilar products to market, because optimizing outcomes
may deliver comparable efficacy to newer biologics, but at
significantly lower cost. We explore the relationship between
drug levels and treatment response, accounting for individual
patient characteristics to determine (i) the adalimumab ther-
apeutic range (i.e., both the minimal effective drug level and
the drug level beyond which response plateaus) and (ii)
whether drug level predicts longer-term response. Given the
nature of this real-world dataset, findings are generalizable to
clinical practice.
RESULTS
Description of the cohort and patient characteristics
At the time of the data cut in April 2017, 2028 patients were
currently or previously receiving adalimumab monotherapy
within the BSTOP cohort. Of these, 1,242 consented to give
longitudinal serum samples; within this, serum samples were
actually collected from 833 patients. Baseline characteristics
were similar between those providing and not providing
samples (Table 1, and see Supplementary Table S1 online). Of
the 833 patients providing serum samples, 544 patients also
had Psoriasis Area and Severity Index (PASI) data within 12
months of starting adalimumab (Figure 1). These 544 patients
were included in the analysis (Table 1), and of these, 375
(69%) were biologic naı¨ve.
The demographics and clinical characteristics of the cohort
were consistent with severe disease (predominantly male,
with an elevated body mass index and mean baseline PASI of
13.5 (standard deviation ¼ 6.7) (Table 1)). Drug levels were
sampled according to standard clinical care (median timeJournal of Investigative Dermatology (2019), Volume 139from last dose ¼ 7 days, interquartile range ¼ 6e10 days,
range ¼ 0e14 days, data available on n ¼ 349 samples),
giving a mean drug level of 5.83 mg/ml (standard deviation ¼
3.86, range ¼ 0.01e22 mg/ml).
As Figures 1 and 2 show, three datasets were derived: a
therapeutic range dataset to investigate the relationship be-
tween drug levels and same-day response, an early dataset to
investigate the relationship between drug levels taken before
12 weeks and the 6-month response, and a steady state
dataset to investigate the relationship between drug levels
taken any time after 9 weeks and response 6 months later.
Defining the therapeutic range
Drug level discriminates responders from non-
responders. Using the therapeutic range dataset (drug
levels with PASI recorded on the same day), empirical
receiver operating characteristic curves (Menting et al., 2015)
were generated for all three outcomes. For a 75% improve-
ment in baseline PASI score (PASI75), drug level discrimi-
nated responders from nonresponders with an area under the
curve of 0.74 (95% confidence interval [CI] ¼ 0.68e0.79)
(Figure 3a, Table 2). A lower limit of 3.2 mg/ml identified
patients achieving PASI75 with our preset minimum sensi-
tivity of 80% (red dot on Figure 3a; specificity ¼ 58%, overall
classification accuracy ¼ 73%). This drug level showed
comparable sensitivity for the secondary outcomes of 90%
improvement in baseline PASI score (PASI90) (82%) and
absolute PASI of 1.5 or less (PASI1.5) (85%), but specificity
and overall classification accuracy were lower (see
Supplementary Table S2 online).
Likelihood of response increases with increasing drug level and
then plateaus. Using the therapeutic range dataset (drug
levels with PASI recorded on the same day), a descriptive
concentration effect curve (Menting et al., 2015) was next
generated to confirm that clinical response increases with
increasing drug level, then plateaus for groups with median
drug level of 4.6 mg/ml or greater (red dot on Figure 3b),
corresponding to a percent PASI change of 90.7% (IQR ¼
83.7e99.4, range ¼ 16.2e100). However, the interquartile
ranges on this curve show variability in response, likely
caused by other clinical and confounding factors including
ADAs, time from last dose, sex, age, and disease duration.
Selecting an upper limit of the therapeutic range taking other
covariates into account. To take clinical and confounding
covariates into account, multivariable mixed effects logistic
regression modelling was carried out using the therapeutic
range dataset. The results were consistent with the empirical
analysis: for the primary outcome of PASI75, the best-fitting
model included (transformed) drug level and ethnicity as
covariates (Table 3, and see Supplementary Table S3 online),
and the probability of PASI75 response plateaued with
increasing drug level, supporting the concept of an upper-
bounded therapeutic range (Figure 4). We selected 7 mg/ml
as the upper limit of the therapeutic range because this
achieves our minimum stipulated 80% probability of
response (81%, 95% CI ¼ 76e86) (Figure 4), whereas the
drug level at which the concentration effect curve appeared
Table 1. Summary statistics for the full cohort, therapeutic range dataset, early dataset, and steady state dataset1
Covariate
Full Cohort
(n [ 544 patients
with 961 samples)
Therapeutic Range Dataset
(n [ 303 patients
with 409 samples)
Early Dataset
(n [ 120 patients
with 159 samples)
Steady State Dataset
(n [ 244 patients
with 322 samples)
Mean (SD)
Complete Data,
n (%) Mean (SD)
Complete Data,
n (%) Mean (SD)
Complete Data,
n (%) Mean (SD)
Complete Data,
n (%)
Baseline PASI 13.5 (6.7) 495 (91.0) 15.9 (5.6) 303 (100.0) 16.2 (6.4) 120 (100.0) 15.9 (5.6) 244 (100.0)
Height (cm) 172.3 (10.3) 520 (95.6) 172.0 (10.1) 295 (97.4) 172.4 (9.3) 114 (95.0) 172.3 (10.3) 239 (98.0)
Weight (kg) 90.9 (20.4) 471 (86.6) 92.3 (20.7) 277 (91.4) 92.3 (22.2) 106 (88.3) 92.9 (21.1) 223 (91.4)
Waist (cm) 102.1 (15.6) 443 (81.4) 103.0 (16.0) 266 (87.8) 103.2 (16.9) 103 (85.8) 103.8 (15.7) 214 (87.7)
BMI (kg/m2) 30.8 (6.7) 465 (85.5) 31.3 (7.2) 274 (90.4) 31.2 (7.3) 106 (88.3) 31.3 (7.0) 221 (90.6)
Age (years) 44.3 (12.2) 544 (100.0) 44.0 (12.3) 303 (100.0) 43.8 (12.4) 120 (100.0) 44.1 (12.2) 244 (100.0)
Disease
duration (years)
22.0 (12.0) 498 (91.5) 21.5 (12.4) 282 (93.1) 20.8 (11.5) 104 (86.7) 21.1 (11.8) 233 (95.5)
n (%) n (%) n (%) n (%)
Ethnicity, white 484 (89.0) 544 (100.0) 272 (89.8) 303 (100.0) 103 (85.8) 120 (100.0) 216 (88.5) 244 (100.0)
Sex, male 338 (62.1) 544 (100.0) 191 (63.0) 303 (100.0) 80 (66.7) 120 (100.0) 161 (66.0) 244 (100.0)
Inflammatory
arthritis
109 (23.5) 464 (85.3) 62 (22.6) 274 (90.4) 27 (26.2) 103 (85.8) 54 (24.1) 224 (91.8)
Ever smoked 298 (56.7) 526 (96.7) 172 (57.9) 297 (98.0) 66 (57.9) 114 (95.0) 141 (58.5) 241 (98.8)
Palm psoriasis 87 (16.9) 515 (94.7) 46 (16.0) 288 (95.0) 21 (19.4) 108 (90.0) 38 (16.4) 232 (95.1)
Biologic naive 375 (68.9) 544 (100.0) 237 (78.2) 303 (100.0) 97 (80.8) 120 (100.0) 189 (77.5) 244 (100.0)
Abbreviations: BMI, body mass index; PASI, Psoriasis Area and Severity Index; SD, Standard Deviation.
1Summaries for the therapeutic range, early, and steady state datasets are restricted to patients with baseline PASI > 10. Height, waist, and body mass index
measurements provided for information only; weight used in modeling.
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(73%, 95% CI ¼ 68e77).
For the PASI90 and PASI1.5 outcomes, drug level
remained the most important determinant of response.
Additional covariates appear significant for PASI90 (baseline
PASI, treatment duration, and biologic-naı¨ve status) and
PASI1.5 (sex and biologic-naı¨ve status). However, this
should be treated with caution given the small number of
patients achieving PASI90 and PASI1.5 (see Supplementary
Tables S3 and S4 and Supplementary Figure S1 online).
Using drug level to predict subsequent response
Early drug levels predict response at 6 months. To determine
whether drug levels indicate response status at later time
points, multivariable logistic regression modeling was carried
out using the early dataset (drug levels taken between 1 and
12 weeks, with PASI recorded at 6 months). For the primary
outcome of PASI75, independent predictors were (trans-
formed) drug level and ethnicity (Table 3, and see
Supplementary Table S5 online). These same covariates were
included in the final PASI90 model, and drug level and
baseline PASI were included in the PASI1.5 model (see
Supplementary Table S4 online). Similar to the analysis using
the therapeutic range dataset (exploring the relationship be-
tween drug levels and response on the same day), the prob-
ability of response at 6 months increases with increasing
early drug level (PASI75: Table 3, and see Supplementary
Figure S2a; PASI90 and PASI1.5: see Supplementary
Table S4 and Supplementary Figures S2b and c). The upper
limit of 7 mg/ml (defined in the therapeutic range dataset)
(Figure 4) corresponds to a 78% (95% CI ¼ 71e85) proba-
bility of 6-month response using early drug levels (Table 2,
and see Supplementary Figure S2a). We also performed asensitivity analysis by fitting the model to very early samples
(4 weeks  1 week after treatment initiation), given our pilot
data showing that higher adalimumab levels in responders
versus nonresponders were detectable at 4 weeks (Mahil et
al., 2013), and acknowledging the overlap between our
early dataset and steady state dataset. We found a similar
relationship between drug levels and PASI75 response (see
Supplementary Table S6 online).
Steady state drug levels predict response 6months later. Finally,
we explored whether steady state drug levels in patients
established on therapy could predict treatment outcomes 6
months later. Multivariable mixed effects logistic regression
modeling was carried out using the steady state dataset
(drug levels taken at least 9 weeks after treatment start, with
PASI recorded 6 months later) (Table 3, and see
Supplementary Table S7 online). Again, for the primary
outcome of PASI75, (transformed) drug level was the single
most important predictor of response (odds ratio [square
root of drug level] ¼ 2.78, 95% CI ¼ 1.83e4.24, P < 0.001)
(Table 3), with increasing probability of response with
increasing drug level (see Supplementary Figure S3a). This
relationship between drug level and response was also seen
using the PASI90 and PASI1.5 outcomes (see
Supplementary Table S4 and Supplementary Figure S3b
and c); the covariates palm psoriasis and biologic-naı¨ve
status were also significant for these outcomes, respectively.
Clinical utility of the therapeutic range
Table 2 gives the standard estimates of clinical utility for
our therapeutic range for PASI75 (3.2e7.0 mg/ml). This
has comparable diagnostic accuracy whether used to
determine response on the same day as the drug level, or
response 6 months later. Bearing our therapeutic rangewww.jidonline.org 117
Figure 1. Flow diagram of patients and samples. Flow diagram showing the rules applied to derive the three datasets. PASI, Psoriasis Area and Severity Index.
N Wilkinson et al.
Therapeutic Drug Monitoring in Psoriasis
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sponding response less than PASI75 had a drug level
below 3.2 mg/ml, and 69 of 171 (40.35%) samples with
a corresponding PASI90 response had a drug level
greater than or equal to 7 mg/ml. This suggests that a
significant proportion of the cohort would benefit from
treatment modification.therapeutic range dataset
Drug level
Drug St
Drug St
Drug St
≥9 weeks after drug start
Drug level
≥9 weeks after drug start
Response PASI
Same day as drug level
Response PASI
6 months (122-243 days) after drug st
Response PASI
6 months (122-243 days) after drug le
Drug level
1-12 weeks after drug start
Sensitivity analysis on very early
drug levels (3-5 weeks)
early dataset
steady state dataset
Figure 2. Timeline of drug levels and
response in each dataset. Timeline
showing when drug level and
response were measured in each of
the three datasets. In the therapeutic
range dataset, response was measured
on the same day as drug level. The
other two datasets were derived to
investigate use of drug levels to
predict response 6 months later: in the
early dataset, response was measured
at 6 months after start of treatment; in
the steady state dataset, response was
measured 6 months after drug level.
Statistical analyses conducted using
each dataset are also shown. ROC,
receiver operating characteristic.
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Key results
In the largest real-world, multicenter cohort across any IMID
to date, we determined the therapeutic range for adalimumab
in moderate to severe psoriasis and calculated probabilities
of response for any given drug level for multiple outcomes
(PASI75, PASI90, and absolute PASI1.5). We also show thatart
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Figure 3. (a) Empirical ROC curve. (b) Concentration effect curve. (a) Empirical ROC curve for PASI75 response. Cutpoint (red dot) chosen to provide a
minimum sensitivity of 80%. (b) Concentration effect curve of median percentage change in PASI against median drug level. These summaries are calculated for
approximately equally sized groups of observations (between 23 and 52) having similar drug levels. Vertical bars: interquartile range (IQR); grey horizontal lines:
indicators of PASI75 and PASI90 response; red dot: drug level beyond which clinical response plateaus. IQR, interquartile range; PASI, Psoriasis Area and
Severity Index; PASI75, 75% improvement in baseline PASI; ROC, receiver operating characteristic.
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points, whether taken early in the treatment course or at
steady state. A minimal effective circulating drug level of 3.2
mg/ml distinguishes PASI75 responders from nonresponders,
and a target drug level of 7 mg/ml provides an 80% proba-
bility of achieving a PASI75 response. As expected, there is a
lower probability (51%) of achieving higher disease clear-
ance (PASI90) at the same target drug level. Measurement of
ADA provides no additional clinical utility, presumably
because of the correlation between drug levels and ADAs.
These key findings support the practical utility of measuring
drug levels at routine clinical visits (irrespective of timing in
relation to drug administration, and despite not being at
trough levels) and provide drug level thresholds at which to
consider changes in adalimumab treatment.Table 2. Diagnostic accuracy of the therapeutic range for
Drug Levels and Resp
(Same Day)
Cutpoint1 (mg/ml) 3.2 7
Sensitivity 80.28 38.
Specificity 57.60 84.
Overall classification accuracy 73.35 52.
Positive predictive value 81.14 85.
Negative predictive value 56.25 37.
AUC (95% CI) 0.74 (0.68e0.79)
Response rate: all samples 69.44
Response rate: samples with drug level < cutpoint2 43.75 62.
Response rate: samples with drug level  cutpoint2 81.14 85.
Probability of response3 (95% CI) 65 (60e71) 81 (76
Analyses are based on 409 samples from 303 patients for the therapeutic range,
from 244 patients for the steady state dataset.
Abbreviations: AUC, area under the curve; CI, confidence interval.
1A cutpoint of 3.2 indicates that samples with a drug level of 3.2 mg/ml or gre
2Response rates for samples above and below cutpoints are equivalent to posi
3Expressed as percentage. Derived from the final multivariable models given iContext and clinical implications
Our findings are consistent with the only other study con-
ducted in psoriasis, which was dual-center and reported a
therapeutic range of 3.51 to 7.00 mg/ml (Menting et al., 2015)
but did not take into account clinical or other covariates such
as ADAs, nor comment on clinical utility. This work builds on
our previous pilot data showing that adalimumab levels at 4
weeks were significantly higher in responders than non-
responders (Mahil et al., 2013). Very few studies across any
IMID have paid attention to early drug levels, and to our
knowledge, only one small study in IBD (Baert et al., 2014)
has looked at early adalimumab levels as a predictor of
subsequent treatment response. This may open up a powerful
clinical opportunity to optimize therapy before drug levels
have reached steady state, well ahead of clinical relapse.PASI75 response
onse
Drug Levels as a Predictor of Subsequent Response
(6 Months)
Early Steady State
3.2 7 3.2 7
38 86.61 40.18 77.46 39.44
80 44.68 74.47 55.96 84.40
57 74.21 50.31 70.19 54.66
16 78.86 78.95 77.46 83.17
72 58.33 34.31 55.96 41.63
0.70 (0.59e0.80) 0.72 (0.66e0.78)
70.44 66.15
28 41.67 65.69 44.04 58.37
16 78.86 78.95 77.46 83.17
e86) 61 (51e70) 78 (71e85) 77 (71e83) 64 (58e70)
on 159 samples from 120 patients for the early samples, and on 322 samples
ater are predicted to correspond with response.
tive predictive value and to 1 e negative predictive value, respectively.
n Table 3.
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Table 3. Final multivariable models for PASI75 response based on drug level and additional covariates (same-day
response e therapeutic range dataset; response 6 months later e early dataset and steady state dataset)
Therapeutic Range Dataset (Mixed Effects Logistic Regression Model)
Covariate
Coefficient
(SE) 95% CI OR (95% CI) P-Value
Marginal/Conditional
Pseudo R2
Number of
Samples
Number of
Responders
(% of Samples)
PASI75 Sqrt (drug level) 1.10 (0.20) 0.69e1.50 2.99 (2.00e4.46) <0.001 0.25/0.38 409 samples from
303 patients
284 (69.44)
Ethnicity, white 1.15 (0.46) 0.24e2.06 3.17 (1.28e7.85) 0.013
Early Dataset (Logistic Regression Model)
Covariate
Coefficient
(SE) 95% CI OR (95% CI) P-Value Pseudo R2
Number of
Samples
Number of
Responders
(% of Samples)
PASI75 Sqrt (drug level) 1.00 (0.26) (0.49e1.52) 2.73 (1.63e4.57) <.001 0.10 159 samples on
120 patients
112 (70.44)
Ethnicity, white 1.05 (0.51) (0.06e2.04) 2.86 (1.06e7.72) .039
Steady State Dataset (Mixed Effects Logistic Regression Model)
Covariate
Coefficient
(SE) 95% CI OR (95% CI) P-Value
Marginal/Conditional
Pseudo R2
Number of
Samples
Number of
Responders
(% of Samples)
PASI75 Sqrt (drug level) 1.02 (0.21) 0.60e1.44 2.78 (1.83e4.24) <.001 0.16/0.50 322 samples on
244 patients
213 (66.15)
Abbreviations: CI, confidence interval; OR, odds ratio; PASI75, 75% improvement in baseline PASI; SE, standard error; Sqrt, square root.
0
0.00
0.25Pr
ob
ab
ilit
y 
of
 re
sp
on
se
0.50
0.75
PASI75
1.00
2 4
Drug level (µg/ml)
6 8 10 12 14
Figure 4. Probability of PASI75 based on same-day drug level (therapeutic
range dataset). Probability of response is split by ethnicity (red ¼ white
ethnicity, teal ¼ all other ethnicities). The grey vertical line is at a drug level of
7 mg/ml, where there is at least 80% probability of response on average for all
patients. This line crosses the red curve for patients of white ethnicity at a
probability of response greater than 80%, but the probability is lower for the
non-white group (teal line).The orange dots indicate the proportion of patients
per group achieving PASI75. The groups are calculated in the same way as for
the concentration effect curve in Figure 2b, and they are not split by other
covariates. The probabilities are marginal predicted means because of the
inclusion of a random effect in the model. Similar curves are seen for
probability of PASI75 in the other datasets (early and steady state). PASI75,
75% improvement in baseline PASI.
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weeks) is also associated with response 6 months later, sug-
gesting that there is potential to optimize therapy even once
patients are established on treatment. Our results may be
generalizable across other IMIDs, given comparable therapeutic
ranges for adalimumab reported in RA (5e8 mg/ml) (Pouw et al.,
2015) and IBD (5.0e5.9 mg/ml or 4.9e7.5 mg/ml [Roblin et al.,
2014; Yarur et al., 2016]) and comparable mean levels in
ankylosing spondylitis (Kobayashi et al., 2012).
A minimal effective drug level indicates the threshold
below which treatment should be modified (dose escalation
or treatment switch). Such an approach has been tested in
IBD, with the Trough Level Adapted Infliximab Treatment
(TAXIT) trial showing similar remission rates in IBD patients
on adjusted infliximab dosing based on drug level, but with
fewer flares than the conventional approach (Vande Casteele
et al., 2015). An upper limit of the therapeutic range identifies
a patient population that might benefit from dose minimi-
zation. This has been simulated in an RA cohort and although
cost effective, it led to a reduction in quality-adjusted life
years for at least a quarter of patients (Krieckaert et al., 2015).
By comparison, our modeling approach may have an
advantage in allowing for individualized prediction of
response. Indeed, our data indicate that both the stringency
of the outcome (for example PASI75 or PASI90) and the
threshold set for the probability of response, need to be
considered when defining the upper limit of the therapeutic
range (and therefore the drug level chosen to implement dose
minimization). This will help optimize cost effectiveness and
minimize the proportion of patients subjected to inappro-
priate dose reduction.
From a biological perspective, the finding that the clinical
response rate plateaus beyond a certain drug level likely re-
flects the point at which most of the TNF in psoriatic skin isJournal of Investigative Dermatology (2019), Volume 139neutralized by adalimumab. In turn, this may indicate that in
patients for whom clinical response plateaus at a lower drug
level, alternative non-TNF pathways possibly play a greater
role in driving their psoriasis.
The finding that biologic-naı¨ve status and ethnicity may
predict longer-term response requires further validation,
because these covariates were not consistent across
N Wilkinson et al.
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status does not appear to be important for achieving PASI75,
it does appear to be influential for achieving clearance
(PASI90 or PASI1.5). This is consistent with existing evi-
dence that biologic-naı¨ve status may influence outcome
(National Institute for Health and Care Excellence, 2018).
Our findings related to ethnicity should be treated with
particular caution, because very few patients within the study
cohort were of non-white ethnicity. Across the BADBIR
cohort as a whole, we found non-white ethnicity to be
associated with a reduced likelihood of response to biologics
up to 1 year (Warren et al., 2018).
Finally, we have confirmed serum drug level to be the
single most important factor determining treatment response,
whether sampled a few weeks after treatment initiation or at
steady state. This underpins the importance of taking drug
levels into account when searching for biomarkers and
mechanisms of treatment response, such as genetic factors.
Indeed, the need to incorporate a richer set of clinical in-
formation, such as seropositivity and disease duration, was
recently highlighted in an innovative crowdsourced assess-
ment of the common genetic contribution to predicting TNF
antagonist treatment response in RA (Sieberts et al., 2016).
Strengths and limitations
A key strength of this study is high external validity, because
more than 50% of all UK psoriasis patients taking biologics are
registered on BADBIR, and 95% of UK dermatology centers
prescribing biologics for psoriasis contribute data to BADBIR.
To maximize inclusivity, generalizability, and sample size, we
developed a prespecified research protocol with inclusion
criteria designed to capture a truly representative patient sam-
ple. This approach, together with the real-world nature of the
cohort necessitating pragmatic sampling, introduces heteroge-
neity into our dataset that reflects our strategy to maximize in-
clusivity and minimize selection bias.
In terms of potential limitations, the validity of the ther-
apeutic range is limited to within 1 year of the start of
treatment, because this was the selected cohort duration.
Most patients in the UK receive the licensed dose for ada-
limumab (40 mg every 2 weeks), so although dose escala-
tion would be a logical clinical strategy for individuals with
subtherapeutic drug levels, this requires confirmation in a
clinical trial setting and would have pharmacoeconomic
implications. On the other hand, the advent of adalimumab
biosimilars at a fraction of the cost of the original drug,
means that dose optimization strategies remain highly rele-
vant. Another potential limitation is use of pragmatic serum
sampling at routine clinic visits; to account for the timing of
samples we included time from last dose as a covariate, and
although this was not significant at the univariate level, we
only had these data available on around a third of samples.
Nevertheless, we identified a range comparable to that of
Menting et al. (2015), who reported on trough drug levels,
suggesting that limiting sampling to trough levels may not be
an absolute requirement. Finally, covariates are not always
consistent across outcomes or datasets because of statistical
artefacts when using different subsets of patients—thus, our
findings require replication. Indeed, the model fit as
measured by pseudo R2 indicates that although drug level isimportant, this model could potentially be improved using
covariates that have not been considered in this study.
CONCLUSIONS
We provide evidence to support the proactive measurement
of drug levels in the management of psoriasis with adalimu-
mab therapy. Drug levels taken both early and at steady state
during the treatment course could be used to predict and
therefore optimize clinical outcome. These findings are of
potential relevance to other IMIDs.
MATERIALS AND METHODS
Ethics approval
The study was conducted in the spirit of the 1996 International
Conference on Harmonisation in Good Clinical Practice (ICH-GCP)
1996 and in accordance with the 2008 Declaration of Helsinki. The
study protocol was approved by The South East London REC 2 Ethics
Committee (11/H0802/7). Written informed consent was obtained
from all subjects before enrolment.
Patients and setting
BSTOP is a prospective, multicenter (n ¼ 60) observational study for
establishing clinically relevant markers of outcomes to systemic
therapies in people with severe psoriasis. All adults in theUK fulfilling
the BSTOP inclusion criteria (BSTOP protocol available at https://bit.
do/BSTOPDOCS) and enrolled onto BADBIR (http://www.badbir.org/)
were invited to participate. BADBIR has recruited more than 12,000
psoriasis patients since 2007 and is unique worldwide in terms of size
and depth of phenotyping. Inclusion criteria include dermatologist’s
diagnosis of psoriasis; age older than 16 years; and started taking, or
switched to, a conventional systemic therapy or a biological therapy
within the previous 6 months. Detailed information is recorded,
including demographics, comorbidities, treatments, and adverse
effects. Clinical response is assessed longitudinally using the criterion
standard assessment tool, the PASI.
Pharmacokinetic measurements
Venous blood samples were collected between June 2009 and
December 2016 during routine clinic reviews; samples from some
BSTOP patients were taken between 2009 and 2011 as part of a pilot
study with the same inclusion criteria. Samples were taken without
reference to treatment administration (i.e., trough/nontrough not
specified) and immediately centrifuged at 2,000g for 10 minutes, and
serum aliquots were frozen ate80 C. In this pragmatic study, samples
were not collected from every patient at every time point. Samples
within the first year of treatment (n ¼ 961, maximum ¼ 4 samples/
patient) were selected and sent in batches to Sanquin (Amsterdam,
The Netherlands) for measurement of adalimumab concentration
(ELISA, mg/ml [Menting et al., 2015]) and ADA (radioimmunoassay,
ADA positive cutoff > 12 arbitrary units/ml [Menting et al., 2015]).
Outcome measures
Primary treatment response was defined as achieving PASI75; sec-
ondary outcomes were (i) PASI90 and (ii) an absolute measure of
response, PASI of 1.5 or less (see results in Supplementary Materials
online). Baseline PASI was defined as the most recent PASI recorded
before the date of the first drug dose within the preceding 6 months
(Iskandar et al., 2015; Warren et al., 2015).
Statistical methods
Analyses for PASI75 and PASI90 responses were restricted to pa-
tients with baseline PASI greater than 10 as an accepted criterion
for severe disease (National Institute for Health and Carewww.jidonline.org 121
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122Excellence, 2018) and to minimize confounding due to pre-biologic
treatments—of particular relevance in this real-world dataset.
Identification of therapeutic range. The therapeutic range
dataset (Figures 1 and 2) included samples that were taken at steady
state (9 weeks [Awni et al., 2003]), with PASI scores recorded on
the same day. Empirical receiver operating characteristic curve
analysis (Menting et al., 2015) was used to identify the lower limit of
the therapeutic range—specifically, the drug level at which re-
sponders are detected with a minimum sensitivity of 80%.
A descriptive concentration effect curve (Menting et al., 2015)
was generated to confirm that clinical response plateaus beyond a
certain drug level. Multivariable mixed effects logistic regression
was then used to identify an upper drug level and to explore the
relationship between drug level and treatment response in the
presence of other relevant covariates. A random intercept term was
used to account for correlation between repeated samples on the
same patient. Univariate mixed effects logistic regression models
explored the relationship between treatment response and (i) drug
level(ii) other confounding covariates including ADA, time from last
dose, sex, age, and disease duration. For continuous covariates, the
best-fitting simple nonlinear transformation was chosen based on
reduction in the Akaike Information Criterion. Covariates associated
with response at significance level P < 0.1 were taken forward to the
multivariable modeling stage. Forward selection techniques were
then used, with covariate inclusion based on significance level
P < 0.05. Pseudo R2 (McFadden for fixed effect models, conditional
and marginal for mixed models [Nakagawa and Schielzeth, 2013])
and Akaike Information Criterion were calculated to assess model
fit. Finally, an upper limit of the therapeutic range was defined based
on this multivariable model for PASI75, with the target probability of
response set at 80%.
Using drug level to predict subsequent response. To investi-
gate whether drug level predicts subsequent outcome, two further
datasets were derived: an early dataset comprising samples taken
between 1 and 12 weeks with a corresponding PASI 6 months
(122e243 days) after start of treatment and a steady state dataset
comprising samples taken at steady state (9 weeks [Awni et al.,
2003]) with a corresponding PASI 6 months (122e243 days) after
the sample date. Multivariable mixed effects logistic regression
models were considered to explore the relationship between drug
level and other covariateswith patient response 6months later. For the
early dataset, a random effect was not included because of the small
number of patients with multiple samples. All analyses were carried
out using Stata, version 14 (StataCorp, 2015) on a complete case basis.
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